144448-01-1Relevant articles and documents
N-[18F]fluoroethylpiperidin-4ylmethyl acetate, a novel lipophilic acetylcholine analogue for PET measurement of brain acetylcholinesterase activity
Kikuchi, Tatsuya,Zhang, Ming-Rong,Ikota, Nobuo,Fukushi, Kiyoshi,Okamura, Toshimitsu,Suzuki, Kazutoshi,Arano, Yasushi,Irie, Toshiaki
, p. 2577 - 2583 (2005)
The reduction of acetylcholinesterase (AChE) activity in the brain has been measured in dementia disorders such as Alzheimer's disease and dementia with Lewy bodies using 11C-labeled acetylcholine analogues, N-[ 11C]methylpiperidin-4-yl acetate and propionate, and positron emission tomography (PET). Our aim was to develop an 18F-labeled acetylcholine analogue useful for brain AChE mapping with PET, since 18F, with a longer half-life, has advantages over 11C. In a preliminary study, a series of N-[14C]ethylpiperidin-3-yl or -4-ylmethanol esters (acetyl and propionyl esters) were newly designed and evaluated in vitro regarding the reactivity with and specificity to AChE using purified human enzymes, leading to a novel 18F-labeled acetylcholine analogue, N-[18F]fluoroethylpiperidin-4-ylmethyl acetate. In rat experiments, the 18F-labeled candidate showed desirable properties for PET AChE measurement: high brain uptake of the authentic ester, high AChE specificity, a moderate hydrolysis rate, and low membrane permeability (metabolic trapping) of the metabolite.